Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Gastroenterology Pubmed

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Baert, F J; D'Haens, G R; Peeters, M; Hiele, M I; Schaible, T F; Shealy, D; Geboes, K; Rutgeerts, P J
Gastroenterology , Volume 116 (1): 7 – Jan 26, 1999
Download PDF
Loading next page...
 
/lp/pubmed/tumor-necrosis-factor-alpha-antibody-infliximab-therapy-profoundly-umVklDCsRN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0016-5085
DOI
10.1016/s0016-5085(99)70224-6
pmid
9869598

Abstract

Journal

Gastroenterology – Pubmed

Published: Jan 26, 1999

There are no references for this article.